Introduction {#sec1}
============

Considering the involvement of genetic and environmental factors in tumorigenesis \[[@B1],[@B2]\], it is very informative to discover cancer-associated SNPs (single-nucleotide polymorphisms) \[[@B3]\]. The inconclusive roles of SNPs in specific cancer types suggest that pooled analysis is warranted. A meta-analysis containing 11,204 subjects reported that the rs699947 polymorphism within the *VEGF* (vascular endothelial growth factor) gene was associated with an increased risk of bladder cancer and renal cell carcinoma in Asians \[[@B4]\]. Another meta-analysis with 34,911 cases and 48,329 controls showed the genetic relationship between the *BRCA2* (BRCA2 DNA repair associated) rs144848 polymorphism and the overall risk of cancer \[[@B5]\].

The human *mTOR* (mammalian target of rapamycin) gene, also called *FRAP* (FKBP12 rapamycin-associated protein), functions as an essential serine-threonine kinase during signal transduction and is involved in the biological processes of cellular proliferation, cell cycle, cell motility, cell survival, or autophagy \[[@B6],[@B7]\]. The abnormal function of mTOR signaling is thought to be associated with oncogenesis \[[@B8]\]. Inhibition of the PI3K (phosphatidylinositol 3-kinase)/AKT/mTOR signaling pathway is employed in therapeutic approaches for certain cancer types \[[@B11]\]. Two polymorphisms, rs2295080 and rs2536, have been identified in the human *mTOR* gene, mapping to chromosome 1p36.22 \[[@B12]\]. In the present study, we are interested in evaluating the possible effect of the two polymorphisms on the susceptibility to different cancers through a series of analyses.

Unlike four previously reported meta-analyses \[[@B13]\], this meta-analysis features newly published articles, and we utilized a different strategy for a comprehensive analysis. Three factors, including cancer type, genotyping method and control source, were considered for the subgroup analyses. Importantly, we performed FPRP analysis, TSA, and eQTL analysis to assess pooled data and the correlation between genotype and gene expression.

Methods {#sec2}
=======

Study selection {#sec2-1}
---------------

We retrieved studies from four online databases (updated to April 2020), PubMed, Embase (Excerpta Medica database), Cochrane, and WANFANG. Supplementary Table S1 presents our main search terms. Next, we screened the obtained articles, referring to the guidelines of PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) \[[@B17]\], and relevant publications \[[@B18],[@B19]\]. Selection factors included overlapping or duplicated data; reviews, case reports, and trials; cellular or animal assays; conference abstracts; meta-analyses; and other diseases, genes or SNPs. The genotype frequency distribution in controls was required to follow HardyñWeinberg equilibrium (HWE). The genotype frequency data of the *mTOR* gene rs2295080 and rs2536 polymorphisms in both cancer cases and negative controls needed to be extractable from the studies.

Information extraction {#sec2-2}
----------------------

We extracted the information independently and utilized a table to summarize the following features: first author name, year of publication, genotypic/allelic frequency, cancer type, source of control, genotyping method, and sample size. We also evaluated the methodological quality of each article with a quality score, as reported previously \[[@B20],[@B21]\]. When the quality score was \>9, the study was considered high quality.

Pooled analysis {#sec2-3}
---------------

The ORs (odds ratios), 95% CIs (confidence intervals), and *P*~Association~ values (*P* values of the association test) were calculated to evaluate association strength and properties. Six genotype comparisons, namely, allele (allele (G vs. T) for rs2295080; allele (C vs. T) for rs1536), homozygote (GG vs. TT; CC vs. TT), heterozygote (TG vs. TT; TC vs. TT), dominant (TG+GG vs. TT; TC+CC vs. TT), recessive (GG vs. TT+TG; CC vs. TT+TC), and carrier (carrier (G vs. T); carrier (C vs. T)) comparisons, were used. An overall meta-analysis and subsequent subgroup analyses according to three factors (control source, genotyping method, and cancer type) were conducted. A random-effects model was used when *I*^2^ \> 50.0% or *P*~heterogeneity~ (*P* value of the heterogeneity) \< 0.05. When using Egger's/Begg's tests, *P*~Egger~ (*P* value of Egger's test) \<0.05 and *P*~Begg~ (*P* value of Begg's test) \<0.05 indicate the presence of large publication bias. A stable OR value during sensitivity analysis reflects the robustness of the result to a certain extent. Stata software (StataCorp LP, U.S.A.) was used for the above analyses.

FPRP analysis {#sec2-4}
-------------

We also performed false-positive report probability (FPRP) analysis on the positive data from the pooled analyses, as described previously \[[@B22],[@B23]\]. The chi-square test was adopted for the evaluation of the genotype frequency distributions. Statistical power was also determined. Six prior probability levels (0.25, 0.1, 0.01, 0.001, 0.0001, and 0.00001) were applied. A noteworthy association was considered when the FPRP value was less than 0.2 at a prior probability of 0.01

TSA test {#sec2-5}
--------

To further confirm the robustness of the conclusions, we conducted trial sequential analysis (TSA), as described previously \[[@B19],[@B24]\]. TSA viewer software (Copenhagen Trial Unit, Copenhagen) was employed to generate a TSA plot with the required information size (RIS) line and TSA monitoring boundaries with a type I error limit of 5% and a statistical power of 80%.

eQTL analysis {#sec2-6}
-------------

We also utilized datasets of the GTEx (The Genotype-Tissue Expression) project (<http://www.gtexportal.org/home/>) \[[@B25],[@B26]\] to perform an expression quantitative trait loci (eQTL) analysis to predict the correlation between the rs2295080 and rs2536 SNPs and the expression level of the *mTOR* gene (ENSG00000198793.12). Considering the above pooled data, two cell samples (EBV_transformed_lymphocytes and cultured_fibroblasts) and specific tissue samples (esophagus, stomach, and prostate) or blood samples (whole blood) were analyzed. The eQTL violin plots are provided.

Results {#sec3}
=======

Study selection {#sec3-1}
---------------

Briefly, in total, 1114 articles were retrieved from three databases. Among them, 178 articles were first excluded due to duplicated data, and 936 articles were removed due to our exclusion criteria. Then, we obtained 37 full-text articles for evaluating eligibility and ruled out 19 ineligible articles because they lacked full genotype data in both cases and controls and did not conform to HWE. Finally, a total of 18 articles \[[@B16],[@B27]\] from the Chinese population were selected. Of them, 16 case--control studies were pooled for the meta-analysis of rs2295080, while 8 case--control studies were pooled for the meta-analysis of rs2536. We show our detailed study diagram in [Figure 1](#F1){ref-type="fig"} and list the extracted information in [Table 1](#T1){ref-type="table"}. All the included studies were of high quality; that is, all quality assessment scores were greater than nine (Supplementary Table S2).

![Flow chart of eligible article selection](bsr-40-bsr20191825-g1){#F1}

###### Basic information from eligible case--control studies

  First author, year   SNP         Case   Cancer type   Control   Source   Genotyping method                                                            
  -------------------- ----------- ------ ------------- --------- -------- ------------------- ------------------- ------ ----- ----- ------ ----- ---- --------------------
  **Cao, 2012**        rs2295080   454    218           38        1126     294                 RCC                 438    277   45    1153   367   HB   TaqMan
                       rs2536      607    99            4         1313     107                 RCC                 628    128   4     1384   136   HB   TaqMan
  **Chen, 2012**       rs2295080   429    209           28        1067     265                 Prostate cancer     413    259   36    1085   331   HB   TaqMan
                       rs2536      565    96            5         1226     106                 Prostate cancer     585    119   4     1289   127   HB   TaqMan
  **Chen, 2019**       rs2295080   310    201           19        821      239                 Breast cancer       245    198   37    688    272   PB   TaqMan
  **He, 2013**         rs2536      938    179           8         2055     195                 Gastric cancer      1019   170   7     2208   184   PB   TaqMan
  **Huang, 2012**      rs2295080   254    140           23        648      186                 ALL                 353    180   21    886    222   HB   TaqMan
                       rs2536      346    65            6         757      77                  ALL                 448    103   3     999    109   HB   TaqMan
  **Li, 2013**         rs2295080   653    311           40        1617     391                 Prostate cancer     617    382   52    1616   486   PB   TaqMan
                       rs2536      804    192           8         1800     208                 Prostate cancer     894    147   10    1935   167   PB   TaqMan
  **Liu, 2017**        rs2295080   236    145           32        617      209                 Prostate cancer     454    316   37    1224   390   HB   TaqMan
  **Liu, 2014**        rs2536      849    186           13        1884     212                 HCC                 850    188   14    1888   216   HB   TaqMan
  **Qi, 2017**         rs2295080   194    279           101       667      481                 Gastric cancer      297    441   174   1035   789   HB   TaqMan
  **Wang, 2015**       rs2295080   568    394           40        1530     474                 Gastric cancer      607    355   41    1569   437   HB   TaqMan
  **Wen, 2017**        rs2295080   366    170           24        902      218                 Thyroid cancer      295    176   29    766    234   PB   TaqMan
  **Xu, 2015**         rs2295080   482    225           30        1189     285                 Colorectal cancer   459    273   45    1191   363   HB   TaqMan
  **Xu, 2013**         rs2295080   482    246           25        1210     296                 Gastric cancer      497    305   52    1299   409   HB   TaqMan
  **Zhao, 2017**       rs2295080   178    90            15        446      120                 Gastric cancer      174    86    11    434    108   PB   TaqMan
  **Zhao, 2015**       rs2295080   68     50            15        186      80                  ALL                 173    111   12    457    135   HB   PCR-RFLP
                                   27     14            6         68       26                  AML                 173    111   12    457    135   HB   PCR-RFLP
  **Zhao, 2016**       rs2295080   351    197           12        899      221                 Breast cancer       345    212   26    902    264   HB   Sequenom Massarray
                       rs2536      453    100           7         1006     114                 Breast cancer       486    93    4     1065   101   HB   Sequenom Massarray
  **Zhu, 2015**        rs2295080   674    390           49        1738     488                 ESCC                702    362   49    1766   460   PB   TaqMan
  **Zhu, 2013**        rs2536      951    165           7         2067     179                 ESCC                957    157   7     2071   171   PB   NR

Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; ESCC, esophageal squamous cell cancer; HB, hospital-based; HCC, hepatocellular carcinoma; M, major allele (T allele for rs2295080; T allele for rs2536); m, minor allele (G allele for rs2295080; C allele for rs2536); NOS, Newcastle--Ottawa Scale; NR, not reported; PB, population-based; PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism; RCC, renal cell cancer; SNP, single-nucleotide polymorphism.

Pooled analysis of rs2295080 {#sec3-2}
----------------------------

An overall meta-analysis of rs2295080 with 16 case--control studies (9502 cases and 10,965 controls) from the Chinese population was first conducted. As shown in [Table 2](#T2){ref-type="table"}, a reduced susceptibility to cancer was observed in cases compared with controls via three of the genotype comparisons \[heterozygote, *P*~Association~ = 0.017, OR (95% CIs) = 0.90 (0.83--0.98); dominant, *P*~Association~ = 0.031, OR (95% CIs) = 0.90 (0.82--0.99); carrier, *P*~Association~ = 0.009, OR (95% CIs) = 0.93 (0.89--0.98)\] but not in the others.

###### Pooling analysis of *mTOR rs2295080* A/G polymorphism

  Overall/Subgroup             Result             Allele              Homozygote          Heterozygote        Dominant            Recessive           Carrier
  ---------------------------- ------------------ ------------------- ------------------- ------------------- ------------------- ------------------- -------------------
  **Overall**                  OR (95% CIs)       0.93 (0.85--1.01)   0.90 (0.72--1.14)   0.90 (0.83--0.98)   0.90 (0.82--0.99)   0.94 (0.76--1.16)   0.93 (0.89--0.98)
                               *P*~Association~   0.086               0.393               0.017               0.031               0.554               0.009
                               Study              16                  16                  16                  16                  16                  16
                               \[Case/control\]   \[9502/10,965\]     \[9502/10,965\]     \[9502/10,965\]     \[9502/10,965\]     \[9502/10,965\]     \[9502/10,965\]
  **PB**                       OR (95% CIs)       0.88 (0.75--1.04)   0.76 (0.53--1.08)   0.89 (0.74--1.06)   0.87 (0.72--1.05)   0.79(0.58--1.08)    0.92 (0.84--1.00)
                               *P*~Association~   0.129               0.125               0.178               0.148               0.137               0.054
                               Study              5                   5                   5                   5                   5                   5
                               \[Case/control\]   \[3490/3415\]       \[3490/3415\]       \[3490/3415\]       \[3490/3415\]       \[3490/3415\]       \[3490/3415\]
  **HB**                       OR (95% CIs)       0.95 (0.85--1.06)   0.99 (0.73--1.34)   0.91 (0.82--1.01)   0.92 (0.82--1.03)   1.02 (0.77--1.36)   0.94 (0.88--1.00)
                               *P*~Association~   0.347               0.941               0.063               0.133               0.885               0.065
                               Study              11                  11                  11                  11                  11                  11
                               \[Case/control\]   \[6012/7550\]       \[6012/7550\]       \[6012/7550\]       \[6012/7550\]       \[6012/7550\]       \[6012/7550\]
  **TaqMan**                   OR (95% CIs)       0.91 (0.83--0.99)   0.84 (0.69--1.03)   0.89 (0.81--0.98)   0.89 (0.80--0.98)   0.88 (0.73--1.05)   0.93 (0.88--0.98)
                               *P*~Association~   0.027               0.096               0.023               0.021               0.162               0.007
                               Study              13                  13                  13                  13                  13                  13
                               \[Case/control\]   \[8762/9790\]       \[8762/9790\]       \[8762/9790\]       \[8762/9790\]       \[8762/9790\]       \[8762/9790\]
  **Urinary system tumor**     OR (95% CIs)       0.86 (0.76--0.98)   0.92 (0.63--1.33)   0.79 (0.71--0.88)   0.80 (0.72--0.89)   1.00 (0.72--1.42)   0.87 (0.79--0.96)
                               *P*~Association~   0.019               0.654               \<0.001             \<0.001             0.991               0.006
                               Study              4                   4                   4                   4                   4                   4
                               \[Case/control\]   \[2793/3326\]       \[2793/3326\]       \[2793/3326\]       \[2793/3326\]       \[2793/3326\]       \[2793/3326\]
  **Prostate cancer**          OR (95% CIs)       0.88 (0.74--1.04)   0.96 (0.57--1.62)   0.80 (0.70--0.90)   0.82 (0.71--0.94)   1.04 (0.63--1.71)   0.88 (0.79--0.99)
                               *P*~Association~   0.140               0.882               \<0.001             0.004               0.881               0.027
                               Study              3                   3                   3                   3                   3                   3
                               \[Case/control\]   \[2083/2566\]       \[2083/2566\]       \[2083/2566\]       \[2083/2566\]       \[2083/2566\]       \[2083/2566\]
  **leukemia**                 OR (95% CIs)       1.24 (1.05--1.47)   2.25 (1.33--3.82)   1.07 (0.86--1.13)   1.17 (0.95--1.44)   2.25 (1.30--3.91)   1.14 (0.94--1.39)
                               *P*~Association~   0.013               0.003               0.574               0.142               0.004               0.168
                               Study              3                   3                   3                   3                   3                   3
                               \[Case/control\]   \[597/1146\]        \[597/1146\]        \[597/1146\]        \[597/1146\]        \[597/1146\]        \[597/1146\]
  **Digestive system tumor**   OR (95% CIs)       0.95 (0.83--1.08)   0.84 (0.65--1.08)   0.96 (0.85--1.13)   0.96 (0.82--1.12)   0.85 (0.69--1.05)   0.97 (0.90--1.05)
                               *P*~Association~   0.443               0.175               0.773               0.598               0.126               0.480
                               Study              6                   6                   6                   6                   6                   6
                               \[Case/control\]   \[4462/4930\]       \[4462/4930\]       \[4462/4930\]       \[4462/4930\]       \[4462/4930\]       \[4462/4930\]
  **Gastric cancer**           OR (95% CIs)       0.96 (0.81--1.14)   0.85 (0.60--1.21)   1.00 (0.84--1.18)   0.97 (0.80--1.18)   0.85 (0.63--1.10)   0.98 (0.89--1.08)
                               *P*~Association~   0.649               0.364               0.970               0.799               0.299               0.647
                               Study              4                   4                   4                   4                   4                   4
                               \[Case/control\]   \[2612/3040\]       \[2612/3040\]       \[2612/3040\]       \[2612/3040\]       \[2612/3040\]       \[2612/3040\]

Abbreviations: CI, confidence interval; HB, hospital-based; OR, odds ratio; PB, population-based.

Subgroup analyses according to three factors (control source, genotyping assay, and cancer type) were then conducted. As shown in [Table 2](#T2){ref-type="table"}, we observed positive results with the allele, heterozygote, dominant, and carrier comparisons in the subgroup of studies employing "TaqMan" analysis (all OR\<1, *P*~Association~\<0.05) but not in the subgroups analysis by control source.

Similarly, we observed a decreased risk of urinary system tumors via the allele \[allele (G vs. T), *P*~Association~ = 0.019, OR (95% CIs) = 0.86 (0.76--0.98)\], heterozygote \[TG vs. TT, *P*~Association~\<0.001, OR (95% CIs) = 0.79 (0.71--0.88)\], dominant \[TG+GG vs. TT, *P*~Association~\<0.001, OR (95% CIs) = 0.80 (0.72--0.89)\], and carrier \[carrier (G vs. T), *P*~Association~ = 0.006, OR (95% CIs) = 0.80 (0.72--0.89)\] comparisons ([Table 2](#T2){ref-type="table"}). Positive results were observed for prostate cancer via the heterozygote \[TG vs. TT, *P*~Association~\<0.001, OR (95% CIs) = 0.80 (0.70--0.90)\], dominant \[TG+GG vs. TT, *P*~Association~ = 0.004, OR (95% CIs) = 0.82 (0.71--0.94)\], and carrier \[carrier (G vs. T), *P*~Association~ = 0.027, OR (95% CIs) = 0.88 (0.79--0.99)\] comparisons ([Table 2](#T2){ref-type="table"}). These results indicated that the TG genotype of *mTOR* rs2295080 is likely to be associated with a decreased susceptibility to urinary system tumors and specific prostate cancers in Chinese patients. However, we detected negative results in the subgroup of studies on digestive system tumors and specific gastric cancers ([Table 2](#T2){ref-type="table"}, all *P*~Association~\>0.05).

Interestingly, we observed an increased risk for leukemia in cases in the allele \[allele (G vs. T), *P*~Association~ = 0.013, OR (95% CIs) = 1.24 (1.05--1.47)\], homozygote \[GG vs. TT, *P*~Association~ = 0.003, OR (95% CIs) = 2.25 (1.33--3.82)\], and recessive \[GG vs. TT+TG, *P*~Association~ = 0.004, OR (95% CIs) = 2.25 (1.30--3.91)\] comparisons, suggesting a potential relationship between the GG genotype of *mTOR* rs2295080 and an increased leukemia risk in the Chinese population. We present the forest plot data of the subgroup analysis by disease type in [Figure 2](#F2){ref-type="fig"}A (homozygote comparison), [Figure 3](#F3){ref-type="fig"}A (heterozygote comparison), Supplementary Figure S1A (allele comparison), Supplementary Figure S2A (dominant comparison), Supplementary Figure S3A (recessive comparison), and Supplementary Figure S4A (carrier comparison). We also present the forest plot data of the subgroup analysis of *mTOR* rs2295080 by control source (Supplementary Figure S5) and genotype method (Supplementary Figure S6).

![Pooled analysis of *mTOR* rs2295080 via the homozygote comparison\
(**A**) Forest plot of the subgroup analysis by cancer type. (**B**) Begg's test. (**C**) Sensitivity analysis.](bsr-40-bsr20191825-g2){#F2}

![Pooling analysis of *mTOR* rs2295080 under the heterozygote model\
(**A**) Forest plot of subgroup analysis by cancer type. (**B**) Begg's test. (**C**) Sensitivity analysis data.](bsr-40-bsr20191825-g3){#F3}

Pooled analysis of rs2536 {#sec3-3}
-------------------------

A total of eight case--control studies with 6653 cases and 7025 controls were included in the pooled analysis of rs2536. As shown in [Table 3](#T3){ref-type="table"}, there was a significant association in the subgroup of studies using "PB" as a control source in the allele \[allele (G vs. A), *P*~Association~ = 0.012, OR (95% CIs) = 1.17 (1.04--1.32)\], heterozygote \[AG vs. AA, *P*~Association~ = 0.047, OR (95% CIs) = 1.21 (1.00--1.45)\], dominant \[AG+GG vs. AA, *P*~Association~ = 0.038, OR (95% CIs) = 1.20 (1.01--1.42)\], and carrier \[carrier (G vs. A), *P*~Association~ = 0.023, OR (95% CIs) = 1.16 (1.02--1.32)\] comparisons. However, we observed negative results in other comparisons ([Table 3](#T3){ref-type="table"}, all *P*~Association~\>0.05).

###### Pooling analysis of *mTOR rs2536* A/G polymorphism

  Overall/Subgroup             Result             Allele              Homozygote          Heterozygote        Dominant            Recessive           Carrier
  ---------------------------- ------------------ ------------------- ------------------- ------------------- ------------------- ------------------- -------------------
  **Overall**                  OR (95% CIs)       1.05 (0.97--1.14)   1.16 (0.80--1.69)   1.03 (0.89--1.18)   1.04 (0.91--1.18)   1.15 (0.80--1.68)   1.04 (0.95--1.14)
                               *P*~Association~   0.252               0.424               0.722               0.604               0.450               0.364
                               Study              8                   8                   8                   8                   8                   8
                               \[Case/control\]   \[6653/7025\]       \[6653/7025\]       \[6653/7025\]       \[6653/7025\]       \[6653/7025\]       \[6653/7025\]
  **PB**                       OR (95% CIs)       1.17 (1.04--1.32)   1.03 (0.58--1.82)   1.21 (1.00--1.45)   1.20 (1.01--1.42)   0.99 (0.56--1.76)   1.16 (1.02--1.32)
                               *P*~Association~   0.012               0.928               0.047               0.038               0.983               0.023
                               Study              3                   3                   3                   3                   3                   3
                               \[Case/control\]   \[3252/3368\]       \[3252/3368\]       \[3252/3368\]       \[3252/3368\]       \[3252/3368\]       \[3252/3368\]
  **HB**                       OR (95% CIs)       0.96 (0.85--1.07)   1.28 (0.78--2.09)   0.92 (0.81--1.05)   0.93 (0.82--1.06)   1.29 (0.79--2.11)   0.95 (0.84--1.07)
                               *P*~Association~   0.445               0.331               0.203               0.296               0.312               0.382
                               Study              5                   5                   5                   5                   5                   5
                               \[Case/control\]   \[3401/3657\]       \[3401/3657\]       \[3401/3657\]       \[3401/3657\]       \[3401/3657\]       \[3401/3657\]
  **TaqMan**                   OR (95% CIs)       1.03 (0.94--1.14)   1.12 (0.74--1.72)   1.00 (0.82--1.21)   1.01 (0.85--1.20)   1.12 (0.73--1.71)   1.03 (0.93--1.14)
                               *P*~Association~   0.484               0.588               0.986               0.930               0.608               0.586
                               Study              6                   6                   6                   6                   6                   6
                               \[Case/control\]   \[4970/5321\]       \[4970/5321\]       \[4970/5321\]       \[4970/5321\]       \[4970/5321\]       \[4970/5321\]
  **Urinary system tumor**     OR (95% CIs)       1.04 (0.90--1.20)   1.01 (0.52--1.98)   1.00 (0.67--1.49)   1.00 (0.69--1.45)   1.00 (0.51--1.94)   1.04 (0.89--1.20)
                               *P*~Association~   0.591               0.966               0.991               0.994               0.994               0.639
                               Study              3                   3                   3                   3                   3                   3
                               \[Case/control\]   \[2380/2519\]       \[2380/2519\]       \[2380/2519\]       \[2380/2519\]       \[2380/2519\]       \[2380/2519\]
  **Digestive system tumor**   OR (95% CIs)       1.05 (0.93--1.19)   1.02 (0.61--1.74)   1.06 (0.93--1.21)   1.06 (0.93--1.21)   1.02 (0.60--1.72)   1.05 (0.92--1.19)
                               *P*~Association~   0.404               0.927               0.378               0.380               0.947               0.452
                               Study              3                   3                   3                   3                   3                   3
                               \[Case/control\]   \[3296/3369\]       \[3296/3369\]       \[3296/3369\]       \[3296/3369\]       \[3296/3369\]       \[3296/3369\]

Abbreviations: CI, confidence interval; HB, hospital-based; OR, odds ratio; PB, population-based.

We present the forest plot data of the subgroup analysis by control source according to the genotype comparisons in [Figure 4](#F4){ref-type="fig"}A (allele comparison), Supplementary Figure S7A (homozygote comparison), Supplementary Figure S8A (heterozygote comparison), Supplementary Figure S9A (dominant comparison), Supplementary Figure S10A (recessive comparison), and Supplementary Figure S11A (carrier comparison). We also provide the forest plot data for the subgroup analyses by genotyping method (Supplementary Figure S12) and cancer type (Supplementary Figure S13).

![Pooling analysis of *mTOR* rs2536 under the allelic model\
(**A**) Forest plot of subgroup analysis by control source. (**B**) Begg's test. (**C**) Sensitivity analysis data.](bsr-40-bsr20191825-g4){#F4}

Heterogeneity, publication bias, and sensitivity analysis {#sec3-4}
---------------------------------------------------------

We used a random-effects model for the meta-analyses of rs2295080 via the allele, homozygote, heterozygote, dominant, and recessive genetic comparisons because substantial between-study heterogeneity was detected \[[Table 4](#T4){ref-type="table"}, *I*^2^ value \>50.0% or *P*~Heterogeneity~ \<0.05\]. For rs2536, a random-effects model was used in the heterozygote ([Table 4](#T4){ref-type="table"}, *I*^2^ value = 57.3%, *P*~Heterogeneity~= 0.022) and dominant (*I*^2^ value = 52.6%, *P*~Heterogeneity~= 0.039) comparisons.

###### Heterogeneity and publication bias analysis of *mTOR* polymorphisms

  SNP             Statistical analysis   Result               Allele    Homozygote   Heterozygote   Dominant   Recessive   Carrier
  --------------- ---------------------- -------------------- --------- ------------ -------------- ---------- ----------- ---------
  **rs2295080**   **Heterogeneity**      *I*^2^               69.2%     67.7%        48.5%          60.6%      64.8%       29.5%
                                         *P*~Heterogeneity~   \<0.001   \<0.001      0.016          0.001      \<0.001     0.128
                                         Random/Fixed         Random    Random       Random         Random     Random      Fixed
                  **Egger's test**       *t*                  1.02      1.09         −0.19          0.49       1.08        0.72
                                         *P*~Egger~           0.327     0.294        0.850          0.634      0.300       0.481
                  **Begg's test**        *z*                  0.59      0.50         0.59           1.22       0.50        0.68
                                         *P*~Begg~            0.558     0.620        0.558          0.224      0.620       0.499
  **rs2536**      **Heterogeneity**      *I*^2^               42.2%     0.0%         57.3%          52.6%      0.0%        32.4%
                                         *P*~Heterogeneity~   0.097     0.916        0.022          0.039      0.898       0.169
                                         Random/Fixed         Fixed     Fixed        Random         Random     Fixed       Fixed
                  **Egger's test**       *t*                  −1.10     2.40         −1.58          −1.36      2.50        −1.32
                                         *P*~Egger~           0.313     0.053        0.166          0.223      0.046       0.235
                  **Begg's test**        *z*                  0.37      2.10         0.62           0.62       1.86        0.62
                                         *P*~Begg~            0.711     0.035        0.536          0.536      0.063       0.536

SNP, single nucleotide polymorphism.

Our sensitivity analysis suggested the stability of the above data. The detailed plots are displayed in [Figures 2](#F2){ref-type="fig"}B--[4](#F4){ref-type="fig"}B, Supplementary Figures S1B--S4B, and Supplementary Figures S7B--S11B. In addition, we assessed publication bias through Egger's and Begg's tests. No large publication bias existed in the majority of genotype comparisons ([Table 4](#T4){ref-type="table"}, *P*~Egger~\>0.05, *P*~Begg~\>0.05), except for the homozygote (*P*~Begg~=0.035) and recessive (*P*~Egger~=0.046) comparisons of rs2536. The funnel plots of Egger's test are presented in [Figures 2](#F2){ref-type="fig"}C--[4](#F4){ref-type="fig"}C, Supplementary Figures S1C--S4C, and Supplementary Figures S7C--S11C.

FPRP analysis and TSA {#sec3-5}
---------------------

To further minimize random errors to confirm the positive association between the *mTOR* rs2295080 polymorphism and the risk of urinary system tumors, prostate cancer, and leukemia, we performed FPRP analysis. As shown in [Table 5](#T5){ref-type="table"}, at a prior probability of 0.1, the FPRP values were all less than 0.2, and the statistical power values were larger than 0.99 for the allele, heterozygote, dominant and carrier comparisons in the assessment of urinary system tumor risk and for the heterozygote and dominant comparisons in the assessment of prostate cancer risk, suggesting a noteworthy association. TSA data for urinary system tumor risk (Supplementary Figure S14) further showed that the cumulative *Z*-curve crossed the TSA monitoring boundary and did not contact the RIS line, suggesting a robust conclusion, although the enrolled study number did not reach the required information size. With regard to the TSA data for prostate cancer risk ([Figure 5](#F5){ref-type="fig"}), we observed that the *Z*-curve crossed both the TSA monitoring boundary and the RIS line, indicating a more robust conclusion.

![Trial sequential analysis for the association between *mTOR* rs2295080 and prostate cancer risk via the dominant comparison](bsr-40-bsr20191825-g5){#F5}

###### FPRP analysis for possible associations between the *mTOR* rs2295080 polymorphism and cancer risk

  Subgroup               Model          OR (95% CI)         *P*^\*^   Statistical Power   Prior probability level                                                             
  ---------------------- -------------- ------------------- --------- ------------------- ------------------------- --------------- ------------- ------------- ------------- -------
  Urinary system tumor   Allele         0.86 (0.76--0.98)   0.024     1.000               ***0.066***               ***0.175***     0.701         0.959         0.996         1.000
                         Heterozygote   0.79 (0.71--0.88)   \<0.001   0.999               ***\<0.001***             ***\<0.001***   ***0.002***   ***0.018***   ***0.156***   0.649
                         Dominant       0.80 (0.72--0.89)   \<0.001   1.000               *\<0.001*                 ***\<0.001***   ***0.004***   ***0.039***   0.290         0.804
                         Carrier        0.87 (0.79--0.96)   0.0056    1.000               ***0.016***               ***0.048***     *0.355*       *0.847*       *0.982*       0.998
  Prostate cancer        Heterozygote   0.80 (0.70--0.90)   \<0.001   0.999               ***0.001***               ***0.002***     *0.020*       *0.170*       0.672         0.953
                         Dominant       0.82 (0.71--0.94)   0.004     0.999               ***0.013***               ***0.038***     0.304         0.815         0.978         0.998
                         Carrier        0.88 (0.79--0.99)   0.033     1.000               ***0.091***               0.231           0.768         0.971         0.997         1.000
  leukemia               Allele         1.24 (1.05--1.47)   0.013     0.986               ***0.039***               ***0.108***     0.570         0.931         0.993         0.999
                         Homozygote     2.25 (1.33--3.82)   0.003     0.067               ***0.108***               0.265           0.799         0.976         0.998         1.000
                         Recessive      2.25 (1.30--3.91)   0.004     0.075               ***0.138***               0.325           0.841         0.982         0.998         1.000

Abbreviations: CI, 95% confidence interval; OR, odds ratio; \*, *Chi-square test was used to calculate the genotype frequency distributions;* FPRP value \< 0.2 in italics and bold.

We only observed that the FPRP value was less than 0.2 for the allele comparison in the assessment of leukemia, at a prior probability of 0.1 ([Table 5](#T5){ref-type="table"}). Furthermore, the cumulative *Z*-curve of leukemia risk did not exceed either the TSA monitoring boundary or the RIS line (Supplementary Figure S15), suggesting the need for more evidence for the association between *mTOR* rs2295080 and the risk of leukemia.

eQTL analysis {#sec3-6}
-------------

Finally, we performed expression quantitative trait loci analysis of GTEx portal data to analyze the possible link between the rs2295080 (chr1_11262571_G\_T_b38) and rs2536 (chr1_11106656_T\_C_b38) SNPs and *mTOR* gene expression. As shown in [Figure 6](#F6){ref-type="fig"}, we observed a potential correlation in whole blood samples (*P*=7.34e-23) but not in the prostate tissues or selected cells (EBV_transformed_lymphocytes and cultured_fibroblasts). With regard to rs2536, we did not observe a significant association between the SNPs and *mTOR* expression in most selected samples, except the cells in the cultured_fibroblasts dataset (Supplementary Figure S16, *P*=8.49e-4).

![eQTL analysis of *mTOR* rs2295080 in certain cells or tissues within the GTEx database\
(**A**) Cells from the EBV_transformed_lymphocytes dataset; (**B**) prostate; (**C**) cells from the cultured_fibroblasts dataset; (**D**) whole blood.](bsr-40-bsr20191825-g6){#F6}

Discussion {#sec4}
==========

Publications with different conclusions on the effect of *mTOR* polymorphisms on cancer risk were retrieved. It was reported that *mTOR* rs2295080 may be associated with susceptibility to gastric cancer in the Chinese population \[[@B35],[@B36]\]. However, a negative association between *mTOR* rs2295080 and the risk of gastric cancer in Chinese patients was also reported \[[@B40]\]. Therefore, the association between *mTOR* rs2295080 and overall cancer susceptibility has not been comprehensively evaluated. Different study enrolment and analysis strategies were applied in this study compared with four prior meta-analyses \[[@B13]\].

With regard to *mTOR* rs2295080, Zhu and colleagues conducted a meta-analysis of seven case--control studies and showed that *mTOR* rs2295080 may be associated with reduced cancer susceptibility in homozygous, heterozygous and dominant models \[[@B16]\]. In our study, we excluded one article \[[@B44]\] and added some new articles \[[@B29],[@B33],[@B35],[@B40]\]. Because one article contained two case--control studies \[[@B41]\], nine new case-control studies were added in our meta-analysis of *mTOR* rs2295080.

In 2014, Shao et al. carried out a meta-analysis of *mTOR* rs2295080 containing five case--control studies \[[@B27],[@B28],[@B31],[@B32],[@B39]\] and reported a potential link between the wild-type TT genotype of the rs2295080 polymorphism and reduced cancer susceptibility under the dominant model \[[@B13]\]. Herein, we added 11 new case--control studies from 10 articles \[[@B16],[@B29],[@B33],[@B35],[@B40]\]. For the meta-analysis of rs2536, six case--control studies \[[@B27],[@B28],[@B30],[@B43]\] were enrolled, and a negative association was detected via the dominant and recessive comparisons. In this study, we added two new case--control studies \[[@B34],[@B42]\] for an updated meta-analysis.

In total, 10 case--control studies from 9 articles \[[@B16],[@B27],[@B28],[@B31],[@B32],[@B36],[@B38],[@B39],[@B41]\] were included in the meta-analysis of *mTOR* rs2295080 by Zining et al \[[@B15]\]. It was reported that the rs2295080 G allele was related to a reduced risk of genitourinary cancers under a dominant model and an increased risk of acute leukemia under a recessive model \[[@B15]\]. In addition, Zining et al conducted another meta-analysis of *mTOR* rs2536 containing seven case--control studies \[[@B27],[@B28],[@B30],[@B43],[@B45]\] and did not observe a positive association between *mTOR* rs2536 and cancer risk \[[@B15]\]. In the present study, we replaced one thesis \[[@B45]\] with another article with duplicate data \[[@B34]\] and added another new study \[[@B42]\].

Zhang and colleagues enrolled 10 case--control studies from nine articles \[[@B27],[@B28],[@B31],[@B32],[@B38],[@B39],[@B41],[@B42],[@B46]\] to conduct a meta-analysis of *mTOR* rs2295080 and performed subsequent subgroup analysis \[[@B14]\]. They observed a reduced susceptibility to urinary system tumors and digestive system tumors in the cases compared with the controls in GG vs. TT, TG vs. TT, GG+TG vs. TT, and GG vs. TG+TT comparisons (*P*\<0.05, OR\<1) \[[@B14]\], indicating the potential effect of the GG and TG genotypes of *mTOR* rs2295080 on the risk of urinary system tumors and digestive system tumors. However, an increased susceptibility to blood system tumors was observed only in the GG vs. TT comparison (*P*\<0.05, OR\>1). In the present study, we removed one study \[[@B46]\] and added eight new studies \[[@B12],[@B16],[@B29],[@B33],[@B35],[@B40]\] to carry out an updated pooled analysis.

Our findings showed a reduced susceptibility to urinary system tumors in cases compared with controls via the allele (G vs. T), TG vs. TT, TG+GG vs. TT, and carrier (G vs. T) comparisons (*P*\<0.05, OR\<1) and a decreased risk of specific prostate cancers in cases compared with controls via the TG vs. TT, TG+GG vs. TT, and carrier (G vs. T) comparisons (*P*\<0.05, OR\<1). More importantly, we implemented FPRP analysis and TSA to confirm these associations. Nevertheless, we failed to detect a positive conclusion in the subgroups of studies related to digestive system tumors and specific gastric cancers. In addition, even though we also observed an increased risk of leukemia in cases compared with controls in the allele G vs. T, GG vs. TT, and GG vs. TT+TG comparisons (*P*\<0.05, OR\>1), the FPRP and TSA data suggested a lack of association.

Ten case-control studies from nine articles were enrolled in the meta-analysis of *mTOR* rs2536 by Zhang et al. and negative conclusions were observed in the overall meta-analysis and subsequent subgroup analyses \[[@B14]\]. In our study, two studies \[[@B45],[@B46]\] with overlapping data were replaced with another two studies \[[@B27],[@B34]\]. We thus included eight eligible case-control studies in the pooled analysis. We reached similar negative conclusions regarding the association between *mTOR* rs2536 and cancer risk in the overall population and in the subgroup of studies on "urinary system tumors" or "digestive system tumors". Additionally, we added subgroup analyses based on "genotyping method" and "control source". Although a negative result was detected in the subgroup of studies using "TaqMan" for genotyping and "HB" as the control source, there was a positive conclusion in the subgroup of studies using "PB" as the control source in the allele (G vs. A), AG vs. AA, AG+GG vs. AA, and carrier (G vs. A) comparisons (*P*\<0.05, OR\>1), suggesting a potential effect of the AG genotype of rs2536 on the susceptibility to cancer.

The following limitations should be noted. Owing to the very limited sample sizes, we failed to conduct subgroup analyses according to some specific cancer types, such as thyroid cancer and colorectal cancer. Additionally, all case--control studies were performed in the Chinese population. More data in the Caucasian population are needed. Several case--control studies did not utilize population-based controls. For example, we found that hospital-based controls were used in the subgroup of studies on "leukemia". There was potential publication bias within the homozygote and recessive comparisons of rs2536. Genetic and environmental factors may contribute to this bias.

Taken together, our findings summarize currently published evidence comprehensive investigations regarding the genetic relationship between *mTOR* rs2295080/rs2536 polymorphisms and the risk of different cancers. We highlight the positive association between the TG genotype within the *mTOR* rs2295080 polymorphism and a reduced risk of urinary system tumors, especially prostate cancer, in the Chinese population. This will help researchers conduct further experiments to determine the molecular mechanisms. Considering the less than sufficient sample size for the pooled analysis of leukemia and the potential genetic relationship between *mTOR* gene expression and the rs2295080 polymorphism, relevant population-based clinical investigations by clinicians and researchers are warranted.
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